A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting

Ali Al Shehri 1, Abdullah Al-Asmi 2, Abdullah Mohammed Al Salti 3, Abubaker Almadani 4, Ali Hassan 5, Ahmed K Bamaga 6 7, Edward J Cupler 8, Jasem Al-Hashel 9 10, Majed M Alabdali 11, Mohammed H Alanazy 12, Suzan Noori 13

Affiliations

01 January 2022

-

doi: 10.3233/JND-220819

Abstract

Pompe disease is a rare, metabolic, autosomal recessive disorder. Early diagnosis is critical for progressive Pompe disease as delays can significantly alter the clinical course of the disease. Diagnostic modalities, including dried blood spot testing and genetic testing, are available and are effective for diagnosing patients with late-onset Pompe disease (LOPD). However, clinicians face numerous clinical challenges related to the diagnosis of the disease. Two expert group committee meetings, involving 11 experts from the United Arab Emirates, Kuwait, the Kingdom of Saudi Arabia, and Oman, were convened in October 2019 and November 2020 respectively to develop a uniform diagnostic algorithm for the diagnosis of pediatric and adult LOPD in the Arabian Peninsula region. During the first meeting, the specialty-specific clinical presentation of LOPD was defined. During the second meeting, a diagnostic algorithm was developed after a thorough validation of clinical presentation or symptoms, which was performed with the aid of existing literature and expert judgement. A consensus was reached on the diagnostic algorithm for field specialists, such as neurologists, rheumatologists, general practitioners/internal medicine specialists, orthopedic specialists, and pulmonologists. This specialty-specific diagnostic referral algorithm for pediatric and adult LOPD will guide clinicians in the differential diagnosis of LOPD.

Keywords: Arabian Peninsula region; Late-onset Pompe disease; acid alpha-glucosidase; dried blood spot.

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.

Hassnan ZA, Hashmi NA, Makhseed N, Omran TB, Al Jasmi F, Teneiji AA.Orphanet J Rare Dis. 2022 Oct 27;17(1):388. doi: 10.1186/s13023-022-02545-w.PMID: 36303251 Free PMC article. Review.

Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study.

Confalonieri M, Vitacca M, Scala R, Polverino M, Sabato E, Crescimanno G, Ceriana P, Antonaglia C, Siciliano G, Ring N, Zacchigna S, Salton F, Vianello A; AIPO Pneumoloped Group.Orphanet J Rare Dis. 2019 Mar 4;14(1):62. doi: 10.1186/s13023-019-1037-1.PMID: 30832705 Free PMC article.

Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).

Yamauchi M, Nakayama H, Shiota S, Ohshima Y, Terada J, Nishijima T, Kosuga M, Kitamura T, Tachibana N, Oguri T, Shirahama R, Aoki Y, Ishigaki K, Sugie K, Yagi T, Muraki H, Fujita Y, Takatani T, Muro S.Sleep Breath. 2021 Jun;25(2):695-704. doi: 10.1007/s11325-020-02170-6. Epub 2020 Aug 18.PMID: 32808237

Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.

Pascarella A, Terracciano C, Farina O, Lombardi L, Esposito T, Napolitano F, Franzese G, Panella G, Tuccillo F, la Marca G, Bernardini S, Boffo S, Giordano A, Di Iorio G, Melone MAB, Sampaolo S.J Cell Physiol. 2018 Aug;233(8):5829-5837. doi: 10.1002/jcp.26365. Epub 2018 Feb 22.PMID: 29215735

Consensus treatment recommendations for late-onset Pompe disease.

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT; AANEM Consensus Committee on Late-onset Pompe Disease.Muscle Nerve. 2012 Mar;45(3):319-33. doi: 10.1002/mus.22329. Epub 2011 Dec 15.PMID: 22173792 Free PMC article. Review.

References

  1.  
    1. McCall AL, Salemi J, Bhanap P, Strickland LM, Elmallah MK, The impact of Pompe disease on smooth muscle: A review. J Smooth Muscle Res. 2018;54:100–18. doi: https://doi.org/10.1540/jsmr.54.100. - DOI - PMC - PubMed
  2.  
    1. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al.., Pompe disease: Pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020;12:15856–74. doi: https://doi.org/10.18632/aging.103794. - DOI - PMC - PubMed
  3.  
    1. Meena NK, Raben N, Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Biomolecules. 2020;10:1339. doi: https://doi.org/10.3390/biom10091339. - DOI - PMC - PubMed
  4.  
    1. Feeney EJ, Austin S, Chien YH, The value of muscle biopsies in Pompe disease: Identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun. 2014;2:2. doi: https://doi.org/10.1186/2051-5960-2-2. - DOI - PMC - PubMed
  5.  
    1. Toscano A, Rodolico C, Musumeci O, Multisystem late onset Pompe disease (LOPD): An update on clinical aspects. Ann Transl Med. 2019;7:284. doi: https://doi.org/10.21037/atm.2019.07.24. - DOI - PMC - PubMed
  6.  
    1. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al.., Frequency of glycogen storage disease type II in The Netherlands: Implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713–6. doi: https://doi.org/10.1038/sj.ejhg.5200367. - DOI - PubMed
  7.  
    1. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL, Later-onset Pompe disease: Early detection and early treatment initiation enabled by newborn screening. J Pediatr.. 2011;158:1023–7. e1021. doi: https://doi.org/10.1016/j.jpeds.2010.11.053. - DOI - PubMed
  8.  
    1. Mechtler TP, Stary S, Metz TF, Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335–41. doi: https://doi.org/10.1016/S0140-6736(11)61266-X. - DOI - PubMed
  9.  
    1. MENA Pompe Working Group Al Jasmi F, Al Jumah M, Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: Consensus recommendations from an expert group. BMC Neurol. 2015;15:205. doi: https://doi.org/10.1186/s12883-015-0412-3. - DOI - PMC - PubMed
  10.  
    1. Hamamy H, Antonarakis SE, Cavalli-Sforza LL. Consanguineous marriages, pearls and perils: Geneva International Consanguinity Workshop Report. Genet Med. 2011;13:841–7. doi: https://doi.org/10.1097/GIM.0b013e318217477f. - DOI - PubMed
  11.  
    1. el-Hazmi MA, al-Swailem AR, Warsy AS, al-Swailem AM, Sulaimani R, al-Meshari AA, Consanguinity among the Saudi Arabian population. J Med Genet. 1995;32:623–6. doi: https://doi.org/10.1136/jmg.32.8.623. - DOI - PMC - PubMed
  12.  
    1. Tehrani KHN, Sakhaeyan E, Sakhaeyan E, Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology. Electron Physician.. 2017;9:4886–9. doi: https://doi.org/10.19082/4886. - DOI - PMC - PubMed
  13.  
    1. Signs and Symptoms Checklist–Late-onset Pompe Disease. Available at: https://www.pompe.com/-/media/ems/conditions/rarediseases/brands/pompe-u.... Accessed on:06 October 2021.
  14.  
    1. Kishnani PS, Steiner RD, Bali D, Pompe disease diagnosis and management guideline [published correction appears in Genet Med Jun382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]]. . Genet Med. 2006;8(5):267–88. doi:https://doi.org/10.1097/01.gim.0000218152.87434.f3. - DOI - PMC - PubMed
  15.  
    1. Chaudhuri A, Behan PO, Fatigue in neurological disorders. Lancet. 2004;363:978–88. doi: https://doi.org/10.1016/S0140-6736(04)15794-2. - DOI - PubMed
  16.  
    1. Jaradeh S Muscle disorders affecting oral andpharyngeal swallowing. Goyal & Shaker GI Motility, 2006 Available at: http://www.nature.com/gimo/contents/pt1/full/gimo35.html. [Published May 16, 2006]. Accessed on: March 3, 2020.
  17.  
    1. Féasson L, Camdessanche J-P, El Mandhi L, Calmels P, Millet GY, Fatigue et affections neuromusculaires. Ann Readopt Med Phys. 2006;49:289–300. doi: https://doi.org/10.1016/j.annrm2006.04.015. - DOI - PubMed
  18.  
    1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N, A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscu Disord. 2014;24:482–91. doi: https://doi.org/10.1016/j.nmd.2014.03.008. - DOI - PubMed
  19.  
    1. Barnabei MS, Martindale JM, Townsend D, Metzger JM, Exercise and Muscular Dystrophy: Implications and Analysis of Effects on Musculoskeletal and Cardiovascular Systems. Compr Physiol. 2011;1:1353–63. doi: https://doi.org/10.1002/cphy.c100062. - DOI - PubMed
  20.  
    1. Gilchrist JM, Overview of Neuromuscular Disorders Affecting Respiratory Function. Semin Respir Grit Care Med. 2002;23:191–200. doi: https://doi.org/10.1055/s-2002-33027. - DOI - PubMed
  21.  
    1. Furst DE, Amato AA, Iorgo ŞR, Gajria K, Fernandes AW, Epidemology of adult idiopathic inflammatory myopathies in a US.. managed care plan. Muscle Nerve. 2012;45:676–83. doi: https://doi.org/10.1002/mus.23302. - DOI - PubMed
  22.  
    1. Smoyer-Tomic KE, Amato AA, Fernandes AW, Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet Disord. 2012;13:103. doi: https://doi.org/10.1186/1471-2474-13-103. - DOI - PMC - PubMed
  23.  
    1. Mastaglia FL, Phillips BA, Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am . 2002;28:723–41. doi: https://doi.org/10.1016/s0889-857x(02)00021-2. - DOI - PubMed
  24.  
    1. Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR, Clinical Characteristics, Treatment Strategies and Outcome in 62 Patients. Mayo Clin Proc. 2007;82:441–7. doi: https://doi.org/10.4065/82.4.441. - DOI - PubMed
  25.  
    1. Musumeci O, Marino S, Granata F, Central nervous system involvement in late-onset Pompe disease: Clues from neuroimaging and neuropsychological analysis. Eur J Neurol. 2019;26:442–e35. doi: https://doi.org/10.1111/ene.13835. - DOI - PubMed
  26.  
    1. Ünver O, Hacıfazlıoglu NE, Karatoprak E, The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study. Neuromuscul Disord. 2016;26:796–800. doi: https://doi.org/10.1016/j.nmd.2016.09.001. - DOI - PubMed
  27.  
    1. Löscher WN, Huemer M, Stulnig TM, Pompe disease in Austria: Clinical, genetic and epidemiological aspects. J Neurol. 2018;265:159–64. doi: https://doi.org/10.1007/s00415-017-8686-6. - DOI - PMC - PubMed
  28.  
    1. Almeida V, Conceicão I, Fineza I, Screening for Pompe disease in a Portuguese high risk population. Neuromuscul Disord. 2017;27:777–81. doi: https://doi.org/10.1016/j.nmd.2017.03.010. - DOI - PubMed
  29.  
    1. Jastrzebska A, Potulska-Chromik A, Łusakowska A, Screening for late-onset Pompe disease in Poland. Acta Neurol Scand. 2019;140:239–43. doi: https://doi.org/10.1111/ane.13133. - DOI - PubMed
  30.  
    1. Lee JH, Shin JH, Park HJ, Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population. Neuromuscul Disord. 2017;27:550–6. doi: https://doi.org/10.1016/j.nmd.2017.03.005. - DOI - PubMed
  31.  
    1. Fukuhara Y, Fuji N, Yamazaki N, A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3–9. doi: https://doi.org/10.1016/j.ymgmr.2017.10.009. - DOI - PMC - PubMed
  32.  
    1. Jones HN, Crisp KD, Asrani P, Sloane R, Kishnani PS, Quantitative assessment of lingual strength in late-onset Pompe disease. Muscle Nerve. 2015;51:731–5. doi: https://doi.org/10.1002/mus.24523. - DOI - PubMed
  33.  
    1. Montagnese F, Granata F, Musumeci O, Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD). J Inherit Metab Dis. 2016;39:391–8. doi: https://doi.org/10.1007/s10545-015-9913-x. - DOI - PubMed
  34.  
    1. Bertoldo F, Zappini F, Brigo M Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease. J Clin Endocrinol Metab. 2015;100:401–6. doi: https://doi.org/10.1210/jc.2014-2763. - DOI - PubMed
  35.  
    1. Roberts M, Kishnani PS, van der Ploeg AT, The prevalence and impact of scoliosis in Pompe disease: Lessons learned from the Pompe Registry. Mol Genet Metab. 2011;104:574–82. doi: https://doi.org/10.1016/j.ymgme.2011.08.011. - DOI - PubMed
  36.  
    1. Gaeta M, Barca E, Ruggeri P, Late-onset Pompe disease (LOPD): Correlations between respiratory muscles CT and MRI features and pulmonary function. Mol Genet Metab. 2013;110:290–6. doi: https://doi.org/10.1016/j.ymgme.2013.06.023. - DOI - PubMed
  37.  
    1. Reyes-Leiva D, Alonso-Pérez J, Mayos M, Correlation Between Respiratory Accessory Muscles and Diaphragm Pillars MRI and Pulmonary Function Test in Late-Onset Pompe Disease Patients. Front Neurol. 2021;12:6212–57. doi: https://doi.org/10.3389/fneur.2021.621257. - DOI - PMC - PubMed
  38.  
    1. Confalonieri M, Vitacca M, Scala R, Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study. Orphanet J Rare Dis. 2019;14:62. doi: https://doi.org/10.1186/s13023-019-1037-1. - DOI - PMC - PubMed
  39.  
    1. Montagnese F, Barca E, Musumeci O, Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): Unusual features and response to treatment. J Neurol. 2015;262:968–78. doi: https://doi.org/10.1007/s00415-015-7664-0. - DOI - PubMed
  40.  
    1. Ruggeri P, Lo Monaco L, Musumeci O, Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease. Neurol Sci. 2020;41(8):2175–84. doi: https://doi.org/10.1007/s10072-020-04316-6. - DOI - PubMed
  41.  
    1. Gaeta M, Musumeci O, Mondello S, Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: New insights from a comparative study by MRI and respiratory function assessment. Neuromuscul Disord. 2015;25:852–8. doi: https://doi.org/10.1016/j.nmd.2015.09.003. - DOI - PubMed
  42.  
    1. Lukacs Z, Nieves Cobos P, Wenninger S, Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology. 2016;87:295–8. doi: https://doi.org/10.1212/WNL.0000000000002758. - DOI - PMC - PubMed
  43.  
    1. Lorenzoni PJ, Kay CSK, Higashi NS, D’Almeida V, Werneck LC, Scola RH, Late-onset Pompe disease: What is the prevalence of limb-girdle muscular weakness presentation? Arq Neuropsiquiatr. 2018;76:247–51. doi: https://doi.org/10.1590/0004-282x20180018. - DOI - PubMed
  44.  
    1. Teodoro J, Silva M, Zimerman L Neuromuscular disorders. 2019:29 (Suppl 1) [Abstract only]. Available at: https://www.nmd-journal.com/article/S0960-8966(19)30483-3/fulltext. Accessed on: 5 July 2021.
  45.  
    1. Karam C, Dimitrova D, Yutan E, Chahin N, Bright tongue sign in patients with late-onset Pompe disease. J Neurol. 2019;266:2518–23. doi: https://doi.org/10.1007/s00415-019-09455-1. - DOI - PMC - PubMed
  46.  
    1. Hensel O, Schneider I, Wieprecht M, Kraya T, Zierz S, Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease. Orphanet J Rare Dis. 2018;13:57. doi: https://doi.org/10.1186/s13023-018-0794-6. - DOI - PMC - PubMed
  47.  
    1. Pichiecchio A, Sacco S, De Filippi P, Caverzasi E, Ravaglia S, Bastianello S, et al.., Late-onset Pompe disease: A genetic-radiological correlation on cerebral vascular anomalies. J Neurol. 2017;264:2110–8. doi: https://doi.org/10.1007/s00415-017-8601-1. - DOI - PubMed
  48.  
    1. Hensel O, Hanisch F, Stock K, Stoevesandt D, Deschauer M, Müller T, Morphology and function of cerebral arteries in adults with pompe disease. JIMD Rep. 2015;20:27–33. doi: https://doi.org/10.1007/8904_2014_385. - DOI - PMC - PubMed
  49.  
    1. Pérez-López J, Selva-O’Callaghan A, Grau-Junyent JM, Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia. Mol Genet Metab. 2015;114:580-–3. doi: https://doi.org/10.1016/j.ymgme.2015.02.004. - DOI - PubMed
  50.  
    1. Wenninger S, Greckl E, Babacić H, Stahl K, Schoser B, Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): A pilot study. J Neurol. 2019;266:133–47. doi: https://doi.org/10.1007/s00415-018-9112-4. - DOI - PubMed
  51.  
    1. Smith BK, Allen S, Mays S, Martin AD, Byrne BJ, Dynamic respiratory muscle function in late-onset Pompe disease. Sci Rep. 2019;9:19006. doi: https://doi.org/10.1038/s41598-019-54314-8. - DOI - PMC - PubMed
  52.  
    1. Berger KI, Chan Y, Rom WN, Oppenheimer BW, Goldring RM, Progression from respiratory dysfunction to failure in late-onset Pompe disease. Neuromuscul Disord. 2016;26:481–89. doi: https://doi.org/10.1016/j.nmd.2016.05.018. - DOI - PubMed
  53.  
    1. Boentert M, Dräger B, Glatz C, Young P, Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease. J Clin Sleep Med. 2016;12:1623–32. doi: https://doi.org/10.5664/jcsm.6346. - DOI - PMC - PubMed
  54.  
    1. Wens SC, Ciet P, Perez-Rovira A, Lung MRI and impairment of diaphragmatic function in Pompe disease. BMC Pulm Med. 2015;15:54. doi: https://doi.org/10.1186/s12890-015-0058-3. - DOI - PMC - PubMed
  55.  
    1. Guimarães MJ, Winck JC, Conde B, Prevalence of late-onset pompe disease in Portuguese patients with diaphragmatic paralysis - DIPPER study. Rev Port Pneumol. 2017;23:208–15. doi: https://doi.org/10.1016/j.rppnen.2017.02.004. - DOI - PubMed
  56.  
    1. De Vito EL, Monteiro SG, Aruj PK, Blunted Hypercapnic Respiratory Drive Response in Subjects With Late-Onset Pompe Disease. Respir Care. 2016;61:930–5. doi: https://doi.org/10.4187/respcare.03940. - DOI - PubMed
  57.  
    1. Figueroa-Bonaparte S, Segovia S, Llauger J, Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function. PLoS One. 2016;11:e4930163. doi: https://doi.org/10.1371/journal.pone.0163493. - DOI - PMC - PubMed
  58.  
    1. Gutiérrez-Rivas E, Bautista J, Vílchez JJ, Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort. Neuromuscul Disord. 2015;25:548–53. doi: https://doi.org/10.1016/j.nmd.2015.04.008. - DOI - PubMed
  59.  
    1. Rairikar MV, Case LE, Bailey LA, Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c-32-13T > G “late-onset” GAA variant. Mol Genet Metab. 2017;122:99–107. doi: https://doi.org/10.1016/j.ymgme.2017.09.008. - DOI - PMC - PubMed
  60.  
    1. Güngör D, de Vries JM, Brusse E, Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109:174–8. doi: https://doi.org/10.1016/j.ymgme.2013.03.016. - DOI - PubMed
  61.  
    1. Scheidegger O, Leupold D, Sauter R, Findling O, Rösler KM, Hundsberger T, 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: Data from the Swiss Pompe Registry. J Neurol. 2018;265:2783–8. doi: https://doi.org/10.1007/s00415-018-9065-7. - DOI - PubMed
  62.  
    1. Hagemans ML, Winkel LP, Van Doorn PA, Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–7. doi: https://doi.org/10.1093/brain/awh384. - DOI - PubMed
  63.  
    1. Hamed A, Curran C, Gwaltney C, DasMahapatra P, Mobility assessment using wearable technology in patients with late-onset Pompe disease. NPJ Digit Med. 2019;2:70. doi: https://doi.org/10.1038/s41746-019-0143-8. - DOI - PMC - PubMed
  64.  
    1. Boentert M, Karabul N, Wenninger S, Sleep-related symptoms and sleep-disordered breathing in adult Pompe disease. Eur J Neurol. 2015;22:369–e27. doi: https://doi.org/10.1111/ene.12582. - DOI - PubMed
  65.  
    1. Perrin C, Unterborn JN, Ambrosio CD, Hill NS, Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve. 2004;29:5–27. doi: https://doi.org/10.1002/mus.10487. - DOI - PubMed
  66.  
    1. Hagemans ML, Laforêt P, Hop WJ, Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord. 2007;17:537–43. doi: https://doi.org/10.1016/j.nmd.2007.03.006. - DOI - PubMed
  67.  
    1. Mammen AL. Which nonautoimmune myopathies are most frequently misdiagnosed as myositis? Curr Opin Rheumatol. 2017;29(6):618–22. doi: https://doi.org/10.1097/BOR.0000000000000441. - DOI - PMC - PubMed

Page Navigation